Tags

Type your tag names separated by a space and hit enter

Overview of therapeutic drug research for COVID-19 in China.
Acta Pharmacol Sin. 2020 Sep; 41(9):1133-1140.AP

Abstract

Since the outbreak of novel coronavirus pneumonia (COVID-19) in December 2019, more than 2,500,000 people worldwide have been diagnosed with SARS-CoV-2 as of April 22. In response to this epidemic, China has issued seven trial versions of diagnosis and treatment protocol for COVID-19. According to the information that we have collected so far, this article provides an overview of potential therapeutic drugs and compounds with much attention, including favipiravir and hydroxychloroquine, as well as traditional Chinese medicine, which have been reported with good clinical treatment effects. Moreover, with further understanding of SARS-CoV-2 virus, new drugs targeting specific SARS-CoV-2 viral components arise and investigations on these novel anti-SARS-CoV-2 agents are also reviewed.

Authors+Show Affiliations

Laboratory of Immunopharmacology, Shanghai Institute of MateriaMedica, Chinese Academy of Sciences, Shanghai, 201203, China. University of Chinese Academy of Sciences, Beijing, 100049, China.Laboratory of Immunopharmacology, Shanghai Institute of MateriaMedica, Chinese Academy of Sciences, Shanghai, 201203, China.Laboratory of Immunopharmacology, Shanghai Institute of MateriaMedica, Chinese Academy of Sciences, Shanghai, 201203, China. University of Chinese Academy of Sciences, Beijing, 100049, China.Laboratory of Immunology and Virology, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.Laboratory of Immunopharmacology, Shanghai Institute of MateriaMedica, Chinese Academy of Sciences, Shanghai, 201203, China.Laboratory of Immunopharmacology, Shanghai Institute of MateriaMedica, Chinese Academy of Sciences, Shanghai, 201203, China.Laboratory of Immunopharmacology, Shanghai Institute of MateriaMedica, Chinese Academy of Sciences, Shanghai, 201203, China. xktong@simm.ac.cn.Laboratory of Immunopharmacology, Shanghai Institute of MateriaMedica, Chinese Academy of Sciences, Shanghai, 201203, China. jpzuo@simm.ac.cn. University of Chinese Academy of Sciences, Beijing, 100049, China. jpzuo@simm.ac.cn. Laboratory of Immunology and Virology, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. jpzuo@simm.ac.cn.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32555446

Citation

Li, Heng, et al. "Overview of Therapeutic Drug Research for COVID-19 in China." Acta Pharmacologica Sinica, vol. 41, no. 9, 2020, pp. 1133-1140.
Li H, Yang L, Liu FF, et al. Overview of therapeutic drug research for COVID-19 in China. Acta Pharmacol Sin. 2020;41(9):1133-1140.
Li, H., Yang, L., Liu, F. F., Ma, X. N., He, P. L., Tang, W., Tong, X. K., & Zuo, J. P. (2020). Overview of therapeutic drug research for COVID-19 in China. Acta Pharmacologica Sinica, 41(9), 1133-1140. https://doi.org/10.1038/s41401-020-0438-y
Li H, et al. Overview of Therapeutic Drug Research for COVID-19 in China. Acta Pharmacol Sin. 2020;41(9):1133-1140. PubMed PMID: 32555446.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Overview of therapeutic drug research for COVID-19 in China. AU - Li,Heng, AU - Yang,Li, AU - Liu,Fei-Fei, AU - Ma,Xin-Na, AU - He,Pei-Lan, AU - Tang,Wei, AU - Tong,Xian-Kun, AU - Zuo,Jian-Ping, Y1 - 2020/06/17/ PY - 2020/03/17/received PY - 2020/05/10/accepted PY - 2020/6/20/pubmed PY - 2020/9/9/medline PY - 2020/6/20/entrez KW - COVID-19 KW - SARS-CoV-2 KW - anti-SARS-CoV-2 agents KW - favipiravir KW - hydroxychloroquine KW - novel coronavirus pneumonia KW - therapeutic drugs KW - traditional Chinese medicine SP - 1133 EP - 1140 JF - Acta pharmacologica Sinica JO - Acta Pharmacol Sin VL - 41 IS - 9 N2 - Since the outbreak of novel coronavirus pneumonia (COVID-19) in December 2019, more than 2,500,000 people worldwide have been diagnosed with SARS-CoV-2 as of April 22. In response to this epidemic, China has issued seven trial versions of diagnosis and treatment protocol for COVID-19. According to the information that we have collected so far, this article provides an overview of potential therapeutic drugs and compounds with much attention, including favipiravir and hydroxychloroquine, as well as traditional Chinese medicine, which have been reported with good clinical treatment effects. Moreover, with further understanding of SARS-CoV-2 virus, new drugs targeting specific SARS-CoV-2 viral components arise and investigations on these novel anti-SARS-CoV-2 agents are also reviewed. SN - 1745-7254 UR - https://www.unboundmedicine.com/medline/citation/32555446/Overview_of_therapeutic_drug_research_for_COVID_19_in_China_ L2 - https://doi.org/10.1038/s41401-020-0438-y DB - PRIME DP - Unbound Medicine ER -